Azitra, INC. (AZTR) — SEC Filings

Overview

Azitra, INC. (AZTR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 17, 2025: Azitra, Inc. filed an 8-K on December 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes other events and financial statements and exhibits. The company's principal executive offices are located at 21 Business Park Drive, Suite 6, Branf

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 43 neutral, 2 mixed. The dominant filing sentiment for Azitra, INC. is neutral.

Filing Type Overview

Azitra, INC. (AZTR) has filed 23 8-K, 4 S-1, 6 10-Q, 4 DEF 14A, 2 10-K, 4 SC 13G/A, 1 SC 13D/A, 4 SC 13G, 1 S-1/A, 1 10-K/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Azitra, Inc. Faces Delisting Concerns — 8-K · Dec 17, 2025 Risk: high
  Azitra, Inc. filed an 8-K on December 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes other e
• Azitra Files S-1 for Resale of Up to 51.7M Shares, Eyes $18M from Warrants — S-1 · Dec 10, 2025 Risk: high
  Azitra, Inc. (AZTR) is an early-stage clinical biopharmaceutical company focused on precision dermatology, utilizing engineered proteins and topical live biothe
• Azitra, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Nov 25, 2025 Risk: medium
  On November 24, 2025, Azitra, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other
• Azitra's Losses Mount, Cash Dwindles Amid NYSE Delisting Threat — 10-Q · Nov 12, 2025 Risk: high
  Azitra, Inc. (AZTR) reported a significant net loss of $2,764,528 for the three months ended September 30, 2025, an increase from a net loss of $1,009,491 in th
• Azitra, Inc. Files 8-K: Delisting Notice — 8-K · Oct 3, 2025 Risk: high
  Azitra, Inc. filed an 8-K on October 3, 2025, reporting a notice of delisting or failure to satisfy continued listing rules, along with other events and financi
• Azitra, Inc. Enters Material Definitive Agreement — 8-K · Aug 29, 2025 Risk: medium
  Azitra, Inc. announced on August 26, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal ex
• Azitra, Inc. Files 8-K on Security Holder Rights — 8-K · Aug 20, 2025 Risk: medium
  On August 20, 2025, Azitra, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles of in
• Azitra's Q2 Net Loss Widens to $6.03M Amid R&D Spend — 10-Q · Aug 11, 2025 Risk: high
  Azitra, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three
• Azitra Files S-1 for Public Offering, Signaling Biotech Funding Push — S-1 · Jul 18, 2025 Risk: high
  Azitra, Inc. (AZTR) filed an S-1 registration statement on July 18, 2025, for a proposed public offering of securities. The company, classified as a pharmaceuti
• Azitra, Inc. Files 8-K with Corporate Updates — 8-K · Jul 3, 2025 Risk: low
  On July 3, 2025, Azitra, Inc. filed an 8-K report detailing several key corporate actions. The filing includes amendments to its Articles of Incorporation or By
• Azitra, Inc. Files 8-K for Security Holder Vote Matters — 8-K · Jun 23, 2025 Risk: low
  Azitra, Inc. filed an 8-K on June 23, 2025, to report the submission of matters to a vote of its security holders. The filing does not provide details on the sp
• Azitra, Inc. Files 8-K Report — 8-K · Jun 18, 2025 Risk: low
  On June 18, 2025, Azitra, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific material e
• Azitra, Inc. Files 8-K: Financials & Reg FD — 8-K · Jun 17, 2025 Risk: low
  Azitra, Inc. filed an 8-K on May 13, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's princ
• Azitra Schedules Virtual Annual Meeting for June 23 — DEF 14A · May 29, 2025 Risk: low
  Azitra, Inc. filed a Definitive Proxy Statement (DEF 14A) on May 29, 2025, for its Annual Meeting of Stockholders scheduled for June 23, 2025, at 11:00 a.m. EDT
• Azitra, Inc. Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Azitra, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus is on the development of novel treatments for respiratory diseases
• Azitra, Inc. Files 8-K on Operations and Financials — 8-K · May 13, 2025 Risk: low
  Azitra, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The fil
• Azitra Files 8-K on Shareholder Nominations — 8-K · May 2, 2025 Risk: medium
  Azitra, Inc. filed an 8-K on May 2, 2025, to report shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing does not contain specific financial
• Azitra, Inc. Files for Public Offering — S-1 · Apr 28, 2025 Risk: medium
  Azitra, Inc. filed an S-1 registration statement on April 28, 2025, to offer shares to the public. The company, incorporated in Delaware with its principal exec
• Azitra, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Apr 24, 2025 Risk: medium
  On April 24, 2025, Azitra, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and other eve
• Azitra, Inc. Files 2024 Annual Report — 10-K · Feb 24, 2025 Risk: medium
  Azitra, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting its financial condition and business operations. The company, incorporated i
• Azitra, Inc. Files 8-K on Operations and Financials — 8-K · Feb 24, 2025 Risk: low
  On February 24, 2025, Azitra, Inc. filed an 8-K report. The filing indicates that the company is providing information regarding its results of operations and f
• Azitra, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Feb 20, 2025 Risk: low
  Azitra, Inc. filed an 8-K on February 20, 2025, to report on the submission of matters to a vote of its security holders. The filing does not disclose specific
• Azitra, Inc. Files 8-K for Material Agreement — 8-K · Feb 6, 2025 Risk: medium
  On February 4, 2025, Azitra, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibi
• Azitra, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 16, 2025 Risk: medium
  On January 14, 2025, Azitra, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other e
• Azitra, Inc. Calls Special Stockholder Meeting — DEF 14A · Jan 14, 2025 Risk: low
  Azitra, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 14, 2025, to inform stockholders about a Special Meeting. The filing details the company's
• Azitra, Inc. Reports on Security Holder Vote — 8-K · Nov 26, 2024 Risk: medium
  Azitra, Inc. filed an 8-K on November 26, 2024, reporting on a matter submitted to a vote of its security holders on November 20, 2024. The filing does not disc
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Azitra, Inc. Files 8-K on Financials and Operations — 8-K · Nov 13, 2024 Risk: low
  Azitra, Inc. filed an 8-K on November 13, 2024, reporting on events that occurred on November 12, 2024. The filing pertains to the company's results of operatio
• Azitra, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 12, 2024 Risk: low
  Azitra, Inc. filed its 10-Q for the period ending September 30, 2024. The company's fiscal year ends on December 31st. The filing was made on November 12, 2024,
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• Azitra, Inc. 2024 Annual Meeting Proxy Statement Filed — DEF 14A · Oct 9, 2024 Risk: low
  Azitra, Inc. is holding its 2024 Annual Meeting of Stockholders on October 9, 2024. The company, located at 21 Business Park Drive, Branford, CT, is a pharmaceu
• Azitra, Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 12, 2024 Risk: medium
  Azitra, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Spe
• Azitra, Inc. Files 8-K on Operations and Financials — 8-K · Aug 12, 2024 Risk: low
  Azitra, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. T
• Bios Equity Partners Files SC 13D/A for Azitra, Inc. — SC 13D/A · Aug 2, 2024 Risk: medium
  On August 2, 2024, Bios Equity Partners, LP filed an SC 13D/A amendment concerning Azitra, Inc. The filing indicates a change in beneficial ownership for a grou
• SC 13G Filing — SC 13G · Aug 1, 2024
• SC 13G Filing — SC 13G · Jul 29, 2024
• Azitra, Inc. Files 8-K: Material Definitive Agreement — 8-K · Jul 26, 2024 Risk: medium
  On July 23, 2024, Azitra, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed financial statements and exhibits.
• Azitra, Inc. Files S-1/A Amendment — S-1/A · Jul 19, 2024 Risk: medium
  Azitra, Inc. filed an S-1/A amendment on July 19, 2024, to its registration statement. The company, incorporated in Delaware with its principal executive office
• Azitra, Inc. Files S-1 for Public Offering — S-1 · Jul 15, 2024 Risk: medium
  Azitra, Inc. filed an S-1 registration statement on July 15, 2024, to register securities for public offering. The company, incorporated in Delaware with its pr
• Azitra, Inc. Merges with Akari Therapeutics plc — 8-K · Jul 3, 2024 Risk: medium
  On June 27, 2024, Azitra, Inc. filed an 8-K report detailing several key events. The company announced the closing of its previously disclosed merger with Akari
• Azitra, Inc. Calls Special Stockholder Meeting — DEF 14A · Jun 3, 2024 Risk: low
  Azitra, Inc. is holding a Special Meeting of Stockholders on June 3, 2024, to discuss important company matters. The company, located at 21 Business Park Drive,
• Azitra, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Azitra, Inc. (AZTR) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Azitra, Inc. filed a 10-Q report for the period ending March 31, 2024. The comp
• Azitra, Inc. Files 8-K on Operations and Financials — 8-K · May 9, 2024 Risk: low
  Azitra, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, and providing financial statements and exhibits. The f
• Azitra, Inc. Files Amendment No. 1 to 2023 Annual Report — 10-K/A · Apr 29, 2024 Risk: low
  Azitra, Inc. (AZTR) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Azitra, Inc. filed an amendment (10-K/A) to its annual report for the
• Azitra, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 15, 2024 Risk:
  Azitra, Inc. (AZTR) filed a Annual Report (10-K) with the SEC on March 15, 2024. Azitra, Inc. filed its 2023 Form 10-K on March 15, 2024. The company is incorpo
• SC 13G Filing — SC 13G · Feb 27, 2024
• SC 13G/A Filing — SC 13G/A · Feb 26, 2024
• Azitra Reports Entry into Material Definitive Agreement — 8-K · Feb 14, 2024 Risk: medium
  Azitra, Inc. filed an 8-K on February 14, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on February 13, 2024.
• Bayer HealthCare Holds 1.3M Shares in Azitra (AZTR) — SC 13G · Feb 12, 2024 Risk: low
  Bayer HealthCare LLC, a subsidiary of the German pharmaceutical giant Bayer AG, reported beneficial ownership of 1,307,401 shares of Azitra, Inc. (AZTR) common

Risk Profile

Risk Assessment: Of AZTR's 42 recent filings, 6 were flagged as high-risk, 19 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Azitra, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: -$8,721,866
• EPS: N/A
• Debt-to-Equity: 0.89
• Cash Position: $1,401,878
• Operating Margin: N/A
• Total Assets: $4,300,279
• Total Debt: $2,021,103

Key Executives

• Francisco D. Salva
• Faith L. Charles, Esq.
• Todd Mason, Esq.
• Aaron Glenn Louis Fletcher
• Leslie Wayne Kreis, Jr.
• Daniel K. Donahue, Esq.
• Barry Grossman, Esq.
• Matthew Bernstein, Esq.
• Justin Grossman, Esq.
• Delaware

Industry Context

Azitra operates in the precision dermatology and biopharmaceutical sector, focusing on novel topical therapies. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Key trends include the increasing use of AI/ML in drug discovery and a growing demand for targeted therapies for rare and chronic skin conditions.

Top Tags

corporate-governance (7) · material-agreement (6) · filing (6) · sec-filing (5) · 8-K (5) · Biotechnology (4) · 8-k (4) · Pharmaceuticals (4) · 10-Q (4) · financials (4)

Key Numbers

• Shares of Common Stock: 38,944,662 — Maximum shares registered for resale by Selling Stockholders
• Aggregate gross proceeds: $1.57 million — Expected from cash exercise of November Warrants and November Placement Agent Warrants
• Last reported sale price per share: $0.3654 — On NYSE American on December 9, 2025
• Reverse Stock Split ratio: 1:6.66 — Took effect on August 21, 2025
• Net Loss (Q3 2025): $2.76M — Increased from $1.01M in Q3 2024, indicating worsening financial performance.
• Net Loss (9M 2025): $8.72M — Increased from $6.57M in 9M 2024, showing a growing accumulated deficit.
• Total Revenue (9M 2025): $0 — Decreased from $7,500 in 9M 2024, highlighting lack of commercialization.
• Cash and Cash Equivalents: $1.40M — Significant decrease from $4.55M at Dec 31, 2024, indicating rapid cash burn.
• Accumulated Deficit: $66.29M — Increased from $57.57M at Dec 31, 2024, reflecting ongoing losses.
• Cash Used in Operations (9M 2025): $8.33M — High burn rate for a company with no revenue.
• Total Stockholders' Equity: $2.28M — Below NYSE American's $4.0M minimum, leading to a deficiency letter.
• Common Shares Outstanding: 10,204,938 — As of November 11, 2025, indicating potential dilution from equity raises.
• Commission File Number: 001-41705 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 46-4478536 — Company's tax identification number.
• Revenue: $0 — for the three and six months ended June 30, 2025, indicating no commercial products

Forward-Looking Statements

• {"claim":"Bayer HealthCare LLC will maintain its significant stake in Azitra, Inc. for the foreseeable future.","entity":"Bayer HealthCare LLC","targetDate":"December 31, 2024","confidence":"medium"}

Related Companies

AKTX

Frequently Asked Questions